AOD-9604 (2mg Vial) Dosage Protocol

AOD-9604 (2mg Vial) Dosage Protocol

Quickstart Highlights

AOD-9604 dosage protocols are based on this synthetic 16-amino-acid fragment (Tyr-hGH 177–191), which has been studied for its ability to promote lipolysis (fat breakdown) and suppress lipogenesis (fat storage) without increasing IGF-1 levels or inducing insulin resistance. Clinical trials have shown that AOD-9604 displays a safety profile comparable to placebo in obese adults, supporting its use as a well-tolerated option for metabolic support. This educational protocol describes a once-daily subcutaneous administration strategy using a practical dilution to enable clear insulin-syringe measurements.

 
  • Reconstitute: Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration.
  • Typical daily range: 300–500 mcg once daily (gradual titration).
  • Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach  (3 mL = ~0.667 mg/mL)

 

WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–4300 mcg45 units (0.45 mL)
Weeks 5–12500 mcg75 units (0.75 mL)

Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation.

 

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

    Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

 Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).

  • Peptide Vials (AOD-9604, 2 mg each):
    • 8 weeks ≈ 12 vials
    • 12 weeks ≈ 19 vials
    • 16 weeks ≈ 26 vials
  • Insulin Syringes (U‑100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
    • 8 weeks (12 vials): 36 mL → 4 × 10 mL bottles
    • 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
    • 16 weeks (26 vials): 78 mL → 8 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

 Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support reduction of fat mass and enhance fat oxidation over time.
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 300–500 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 2 mg vial (~0.667 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

 Dosing Protocol

Suggested daily titration approach.

    • Start: 300 mcg daily for Weeks 1–4; increase to 500 mcg for Weeks 5–12 as tolerated.
    • Target: 500 mcg daily by Week 5 and maintain through cycle completion.
    • Frequency: Once per day (subcutaneous).
    • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
    • Timing: Morning administration (fasted) is common; rotate injection sites.

 Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

  Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes (U‑100, 29–31 gauge); dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Each 2 mg vial provides approximately 4 days of dosing at 500 mcg/day or 6–7 days at 300 mcg/day.

 How This Works

AOD-9604 is a modified C-terminal fragment of human growth hormone that preserves the lipolytic (fat-reducing) domain while lacking growth-promoting effects. It acts on adipose tissue to stimulate the breakdown of stored fat and inhibit new fat storage (re-esterification) within adipocytes. At the molecular level, prolonged AOD-9604 administration increases β3-adrenergic receptor expression in fat tissue, counteracting obesity-related downregulation of these fat-burning receptors. Unlike full-length hGH, AOD-9604 does not meaningfully raise IGF-1 levels or impair glucose tolerance, resulting in a tolerability profile comparable to placebo in human trials.

 Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Supports decreases in fat mass with gradual increases in fat oxidation; clinical trials reported modest yet statistically significant weight loss (approximately 2.6 kg compared with 0.8 kg for placebo over 12 weeks at 1 mg/day).
  • Preferential reduction of abdominal fat has been observed, mirroring patterns seen with low-dose hGH therapy.
  • Does not meaningfully increase IGF-1 and demonstrates a placebo-like safety profile in human studies; no anti-AOD9604 antibodies were identified.
  • Emerging regenerative potential: preclinical research suggests possible benefits for cartilage repair and bone health.
  • Generally well tolerated; occasional mild injection-site reactions (redness or itching) may occur with subcutaneous administration.

 Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a hypocaloric, protein-forward diet aligned with individual energy needs; AOD-9604 should be regarded as a supportive aid to fat loss rather than a stand-alone solution.
  • Combine resistance training with aerobic activity to reinforce favorable metabolic adaptations.
  • Prioritize adequate sleep and effective stress management to support adherence and recovery.

 Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

  • Clean the vial stopper and skin with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy.

 Recommended Source

We recommend Ion Peptide for high‑purity AOD‑9604 (2 mg).

Why Ion Peptide?

  • High‑purity, third‑party‑tested lots with batch COAs.
  • Consistent, ISO‑aligned handling and documentation.
  • Reliable fulfillment to maintain cold‑chain integrity.

    Shop at Ion Peptide
     

 Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare